Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | HTT | P42858 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 8/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.58 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | IDH1 | O75874 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304565 | 0.88 | EPHX1 (0.59) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1305530 | 0.86 | PPARA (0.55) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1306107 | 0.84 | PPARA (0.60) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL805971 | 0.84 | PPARA (0.61) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL16303954 | 0.84 | PPARA (0.61) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1305271 | 0.84 | CA1 (0.58) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1304908 | 0.84 | MEN1 (0.62) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3372026 | 0.82 | PPARA (0.65) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1304976 | 0.82 | EPHX2 (0.53) | MAPTHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9303663 | 0.81 | MEN1 (0.57) | MAPTHTTNPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | claimed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | claimed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | claimed |
| US-20160280764-A1 | Glycation Cross-link Breakers to Increase Resistance to Enzymatic Degradation | NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY | 2016-09-29 | — | — | US | disclosed |
| US-9309304-B2 | Glycation cross-link breakers to increase resistance to enzymatic degradation | CORNELL UNIVERSITY (US) | 2016-04-12 | — | — | US | disclosed |
| US-20130310539-A1 | Glycation Cross-link Breakers to Increase Resistance to Enzymatic Degradation | NEW YORK SOCIETY FOR THE RELIEF OF THE RUPTURED AND CRIPPLED, MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY | 2013-11-21 | — | — | US | disclosed |
| US-8053449-B2 | Method for inhibiting AGE complex formation | Cell Viable Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | disclosed |
| US-20080076804-A1 | METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION | Cell Viable Corporation | 2008-03-27 | — | — | US | disclosed |
| US-20070099966-A1 | Device and Method for Inhibiting AGE Complex Formation | Cell Viable Corporation | 2007-05-03 | — | — | US | disclosed |
| WO-2007044309-A2 | DEVICE AND METHOD FOR INHIBITING AGE COMPLEX FORMATION | VASIX CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | disclosed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | disclosed |